The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).
M. Y. Al-Marrawi
No relevant relationships to disclose
B. I. Rini
Consultant or Advisory Role - AVEO; GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
L. C. Harshman
Consultant or Advisory Role - Novartis
Research Funding - Genentech; Novartis
G. A. Bjarnason
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
L. Wood
No relevant relationships to disclose
U. N. Vaishampayan
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis; Pfizer
M. J. MacKenzie
No relevant relationships to disclose
J. J. Knox
Research Funding - Bayer; Novartis; Pfizer
N. Agarwal
No relevant relationships to disclose
C. K. Kollmannsberger
No relevant relationships to disclose
M. Tan
No relevant relationships to disclose
S. Y. Rha
No relevant relationships to disclose
F. Donskov
No relevant relationships to disclose
S. A. North
No relevant relationships to disclose
T. K. Choueiri
No relevant relationships to disclose
D. Y. C. Heng
No relevant relationships to disclose